Advertisement

Journal of Neuro-Oncology

, Volume 133, Issue 2, pp 309–313 | Cite as

Impact of treatment on survival of patients with secondary glioblastoma

  • Christina Hamisch
  • Maximilian Ruge
  • Stephanie Kellermann
  • Ann-Cathrin Kohl
  • Inga Duval
  • Roland Goldbrunner
  • Stefan J. Grau
Clinical Study
  • 279 Downloads

Abstract

Data concerning treatment of secondary glioblastoma evolving from previously treated WHO II or III grade tumors are very scarce. The aim of this study was to evaluate the impact of surgical resection and adjuvant treatment on survival in patients with secondary glioblastoma. Thirty-nine patients with secondary glioblastoma evolving from previously treated lower grade gliomas between 2004 and 2015 were included. We evaluated the extent of resection, pathological parameters, adjuvant treatment, as well as survival after malignant transformation. The primary tumor grade was WHO II in 16 (41.0%) and WHO III in 23 (59.0%) patients. Median age was 43 years (range 23–67). Median KPS was 80 (range 60–100) before surgery, and 70 (range 50–100) after surgery. Gross total resection (GTR) of contrast-enhancing disease was achieved in 19 (48.7%) patients. Adjuvant treatment was radio-chemotherapy in 23 (59.0%), radiotherapy in three (7.7%), chemotherapy in five (12.8%) and none in eight (20.5%) patients. Median survival was 11 months (range 1–35) in the entire group. Time since initial diagnosis and previous treatment did not correlate with survival after glioblastoma. Failed GTR, poor KPS after surgery, and no adjuvant treatment were prognostic factors for shorter survival in univariate analysis (p < 0.0001, p = 0.028 and p = 0.003). In selected patients, complete resection and adjuvant treatment may prolong survival in spite of multiple previous therapies.

Keywords

Secondary glioblastoma Low grade glioma Resection Recurrence 

Notes

Funding

Nothing to declare.

References

  1. 1.
    Ohgaki H, Kleihues P (2013) The definition of primary and secondary glioblastoma. Clin Cancer Res 19:764–772. doi: 10.1158/1078-0432.CCR-12-3002 CrossRefPubMedGoogle Scholar
  2. 2.
    Nobusawa S, Watanabe T, Kleihues P, Ohgaki H (2009) IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 15:6002–6007. doi: 10.1158/1078-0432.CCR-09-0715 CrossRefPubMedGoogle Scholar
  3. 3.
    Juratli TA, Kirsch M, Geiger K et al (2012) The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas. J Neurooncol 110:325–333. doi: 10.1007/s11060-012-0977-2 CrossRefPubMedGoogle Scholar
  4. 4.
    McCormack BM, Miller DC, Budzilovich GN et al (1992) Treatment and survival of low-grade astrocytoma in adults–1977–1988. Neurosurgery 31:636–642 (discussion 642) PubMedGoogle Scholar
  5. 5.
    Ramakrishna R, Hebb A, Barber J et al (2015) Outcomes in Reoperated Low-Grade Gliomas. Neurosurgery 77:175–184. doi: 10.1227/NEU.0000000000000753 CrossRefPubMedGoogle Scholar
  6. 6.
    Stummer W, Pichlmeier U, Meinel T et al (2006) Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 7:392–401. doi: 10.1016/S1470-2045(06)70665-9 CrossRefPubMedGoogle Scholar
  7. 7.
    Ohgaki H, Kleihues P (2005) Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 64:479–489CrossRefPubMedGoogle Scholar
  8. 8.
    Delgado-López PD, Corrales-García EM (2016) Survival in glioblastoma: a review on the impact of treatment modalities. Clin Transl Oncol 18:1062–1071. doi: 10.1007/s12094-016-1497-x CrossRefPubMedGoogle Scholar
  9. 9.
    Johnson BE, Mazor T, Hong C et al (2014) Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science 343:189–193. doi: 10.1126/science.1239947 CrossRefPubMedGoogle Scholar
  10. 10.
    Jakola AS, Gulati S, Weber C et al (2011) Postoperative deterioration in health related quality of life as predictor for survival in patients with glioblastoma: A prospective study. PLoS ONE 6:e28592. doi: 10.1371/journal.pone.0028592 CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Quick J, Gessler F, Dützmann S et al (2014) Benefit of tumor resection for recurrent glioblastoma. J Neurooncol 117:365–372. doi: 10.1007/s11060-014-1397-2 CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  • Christina Hamisch
    • 1
  • Maximilian Ruge
    • 2
  • Stephanie Kellermann
    • 1
  • Ann-Cathrin Kohl
    • 1
  • Inga Duval
    • 1
  • Roland Goldbrunner
    • 1
  • Stefan J. Grau
    • 1
  1. 1.Department of NeurosurgeryUniversity Hospital of CologneCologneGermany
  2. 2.Department of Stereotaxy and Functional NeurosurgeryUniversity Hospital of CologneCologneGermany

Personalised recommendations